Plus, news about Adaptilens:
4P-Pharma secures €15M in second closing: The fundraise, which was backed by private investors, will be used to support the French biotech as it uses its “startup studio’s model” to develop single product vehicles. The company’s lead candidate — a CXCR4 antagonist called 4P021 — is currently in Phase 2 development for acute respiratory distress syndrome.
Oncotelic Therapeutics divests cancer assets for $15M: The biotech is selling the rights to its necroptosis cancer drug candidates to Mosaic ImmunoEngineering for $15 million in Mosaic shares. Oncotelic could earn up to $15 million more in shares based on certain milestones.
Adaptilens completes $17.5M Series A: The proceeds will help the Boston-based company advance its “biomimetic intraocular lens” for cataract surgery through the first-in-human trials. The fundraise was led by Perceptive Xontogeny Venture Funds, with support from Pillar VC, 380 Cap and Accanto Partners.